Infection risk is also heightened due to tissue and endothelial damage and immunoparalysis following CRS, as well as the use of steroids and anti-IL6 blockade to treat CRS – a retrospective, multicentre study of BisAb-treated patients with MM revealed that corticosteroid use for the treatment of CRS or ICANS was associated with a significantly increased risk of first infection (HR 2.13) [99]. This evidence concerns the gene IL6 and Miyoshi myopathy.